Overview
Germany specialty pharma provider's Q1 revenue rose 8.9% yr/yr
Q1 adjusted EBITDA fell 7.9% due to operational and one-time effects
Company confirms 2026 full-year guidance despite margin pressure from price declines and higher costs
Outlook
Medios confirms 2026 revenue guidance of €2.0 bln to €2.12 bln
Company expects 2026 EBITDA pre of €94 mln to €102 mln, margin about 4.8%
Medios expects margin improvement in 2026 from cost-cutting and focus on higher-margin products
Result Drivers
PRICE DECLINES AND COST INCREASES - Margin was temporarily weighed by price declines for certain products, shifts in product mix, one-time costs, and higher logistics and energy prices
ONE-TIME EFFECTS - Prior-year quarter included a one-time gain from the sale of a pharmacy in the Netherlands, impacting year-over-year earnings comparison
WORKING CAPITAL IMPROVEMENTS - Significant increase in operating cash flow attributed to improvements in working capital management
Company press release: ID:nEQCcFlga
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
EUR 527.6 mln
Q1 Adjusted Free Cash Flow
EUR 12.5 mln
Q1 EBITDA pre
EUR 21.2 mln
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Medios AG is €24.00, about 62.2% above its May 11 closing price of €14.80
The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 12 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)